Pfizer's Lipitor Sees Big Boost From Medicare

Pfizer is discounting its blockbuster brand Lipitor more aggressively. But, thanks to the economics of Medicare Part D, the product is still benefiting from a big net price increase in 2006. Lipitor's performance is some much needed good news for Pfizer--and maybe even better news for the industry as a whole.

By Michael McCaughan

The success of Pfizer Inc. ’s blockbuster lipid-lowering drug atorvastatin (Lipitor) has always been about the math.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Market Access

More from Pink Sheet